20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells

Planta Medica

Volumn 75, Issue 10, 2009, Pages 1124-1128

  Zhao, Yan ^a   Bu, Luke ^a   Yan, Hang ^c   Jia, William ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Pegasus Pharmaceuticals   (Canada)

Author keywords

Ginsenosides; MDR; P glycoprotein; Protopanaxadiol

Indexed keywords

20 PROTOPAPANAXADIOL; ADENOSINE TRIPHOSPHATASE; CALCEIN; GINSENOSIDE RG 3; GINSENOSIDE RH 2; GLYCOPROTEIN P; PROTOPANAXADIOL; UNCLASSIFIED DRUG; VERAPAMIL; SAPOGENIN;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; LEUKEMIA P 388; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; DRUG ANTAGONISM; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; MICE; P-GLYCOPROTEIN; SAPOGENINS;

EID: 70350755796     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185477     Document Type: Article

References (26)

1. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 1997; 94: 10594-10599
2. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36: 57-104
3. PerryMC. The chemotherapy source book, 2nd edition. Baltimore: Williams & Wilkins; 1996: 1071
4. Barecki-Roach M, Wang EJ, Johnson WW. Many P-glycoprotein substrates do not inhibit the transport process across cell membranes. Xenobiotica 2003; 33: 131-140
5. Kemper EM, Boogerd W, Thuis I, Beijnen JH, van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004; 30: 415-423
6. Leontieva OV, Preobrazhenskaya MN, Bernacki RJ. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin 14-Ohemiadipate. Invest New Drugs 2002; 20: 35-48
7. VarmaMV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359
8. Di Pietro A, Dayan G, Conseil G, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H, Jault J. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships. Braz J Med Biol Res 1999; 32: 925-939
9. Bruce C. Anticancer drug development. San Diego, Calif., London: Academic; 2002: 77-79
10. Radad K, Gille G, Moldzio R, Saito H, Rausch WD. Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res 2004; 1021: 41-53
11. Hasegawa H, Sung JH, Matsumiya S, Uchiyama M, Inouye Y, Kasai R, Yamasaki K. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med 1995; 61: 409-413
12. Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 2003; 69: 235-240
13. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH, Pyo S, Rhee DK. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 2003; 65: 75-82
14. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 2004; 27: 429-435
15. Xie HT,Wang GJ, Chen M, Jiang XL, Li H, Lv H, Huang CR,Wang R, Roberts M. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol Pharm Bull 2005; 28: 383-386
16. Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressingmultidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002; 28: 160-168
17. Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, Bush JA, Li G. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 2004; 82: 431-437
18. Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997; 63: 436-440 (Pubitemid 27399983)
19. Popovich DG, Kitts DD. Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2. Can J Physiol Pharmacol 2004; 82: 183-190
20. Liu GY, Bu X, Yan H, Jia WW. 20S-Protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and ?independent pathways. J Nat Prod 2007; 70: 259-264
21. Yu Y, Zhou Q, Hang Y, Bu X, Jia W. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells. Cancer 2007; 109: 2374-2382
22. Aboudkhil S, Henry L, Zaid A, Bureau JP. Effect of testosterone on growth of P388 leukemia cell line in vivo and in vitro. Distribution of peripheral blood T lymphocytes and cell cycle progression. Neoplasma 2005; 52: 260-266
23. Sharom FJ, Liu R, Romsicki Y, Lu P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies. Biochim Biophys Acta 1999; 1461: 327-345
24. Essodaigui M, Broxterman HJ, Garnier-Suillerot A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 1998; 37: 2243-2250
25. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1997; 1361: 169-176
26. Bruce C, Baguley DJK. Anticancer drug development. San Diego, CA, London: Academic; 2002: 77-90